Bolivia Company Qualification Dossier and RM Authorisation: Requirements and Compliance Calendar

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The applicant entity in Bolivia, meaning the local company holding or seeking the registration, must submit two corporate qualification documents. The first, required by Section 2.2.1, is a copy of the ministerial resolution (Resolución Ministerial) authorizing the company to operate its business. The second, required by Section 2.2.2, is the Certificado de Empresa in force, which must demonstrate that the company’s licence is valid, that its annual review has been completed, that its annual inspection has been passed, and must state whether the company operates as a manufacturer or as an importer. In addition, Section 5.7.2 requires every company to complete its annual review before December 31 of each year. GRZAN’s assessment is that lapse of corporate qualification is the only risk that can affect the entire product portfolio at once. A missing clinical report or an incomplete test file endangers one application; an expired Certificado de Empresa or a lapsed operating authorization endangers every registration held by that company, because the legal basis on which all of those registrations rest is the company’s own standing. Companies operating in Bolivia should therefore monitor corporate standing with the same discipline as product licences, since a portfolio built over years depends on the same underlying authorization remaining alive. The review of these documents at each filing re-confirms that the legal person and its standing remain intact.

2. Legal basis

RegulationReference numberPublication dateProvision
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 2.2.1
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 2.2.2
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 5.7.2
Decreto Supremo (establishing AGEMED)Decreto Supremo N° 2905September 21, 2016Article 2

3. Expert insights

Insight one: the Certificado de Empresa is proof of status, not proof of identity. Section 2.2.2 requires it to establish three things simultaneously: that the licence is valid, that the annual review has been completed, and that the annual inspection has been passed. This means the certificate is inherently time-sensitive. It evidences the company’s compliance condition at the moment of issue, not an enduring legal attribute. Every submission therefore requires a current version of the certificate, and companies cannot rely on historical copies pulled from a previous filing. Teams that habitually reuse dossier modules across applications should explicitly exclude this document from any reuse list and treat it as a per-submission item with its own collection workflow. In practice, teams should track the issue date, review status and inspection results of the certificate in a compliance register, with reissue triggered by any change in those fields.

Insight two: the deadline for the annual review is a nationally uniform December 31. This fixed date is independent of product registration expiry dates. A company that manages its certificates solely against product expiry timelines will, in some year, find its entire pipeline blocked because the corporate annual review has not been completed. GRZAN recommends setting a fixed annual reminder in the certificate calendar, separate from product expiry reminders, and starting the internal review cycle early enough that the certificate can be reissued before year end. Because the deadline falls in the same period as year-end operational peaks, planning the review for the third quarter rather than December itself reduces the risk of missing the statutory date. Because the deadline is identical for every company in the country, demand near year end is heavy, which is a further reason to complete the process early.

Insight three: the copy of the ministerial resolution confirms the right to operate, and it also serves as a proxy indicator of importer capability. Obtaining that authorization means the company has passed a qualification review by the authorities. In importer due diligence, it is a more meaningful compliance signal than turnover figures or commercial references, because it reflects a regulatory assessment of the company rather than its sales performance. A distributor that holds a current ministerial authorization has demonstrated, at least once, that its structure satisfies national requirements for handling regulated health products.

4. Practical recommendations

  1. Establish December 31 each year as a compliance node independent of the product cycle, and start preparations two months in advance (practical estimate), so that the annual review, inspection follow-up and certificate reissue can all be completed before the statutory deadline.
  2. Request a current Certificado de Empresa before every submission and do not reuse an older copy, even one issued only months earlier, since reviewers assess the certificate as of the filing date. A certificate requested directly for the application is also the simplest evidence that the corporate standing was current at that moment.
  3. Write continuing validity of corporate qualification into the representations and warranties clause of the distribution agreement, and define its breach as a contractual default event, giving the manufacturer a remedy if the importer’s standing lapses.
  4. Maintain a compliance calendar for each importer that records the authorization date, the certificate issue dates and the annual review status, so that portfolio-level risk is visible at a glance.

5. Verification checklist

  • □ The copy of the ministerial resolution authorization is a currently valid version
  • □ The company certificate states that the annual review and annual inspection have been completed
  • □ The company certificate identifies whether the holder is a manufacturer or an importer
  • □ A separate reminder has been set for the annual December 31 deadline
  • □ The distribution agreement contains a clause on continuing validity of corporate qualification

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support in Bolivia for manufacturers, importers and authorized representatives, covering corporate qualification review, certificate management, dossier preparation and regulatory correspondence. For assistance with company qualification documents and registration maintenance, contact info@grzanglobal.com. Support covers coordination of Form 027 signing, importer due diligence on technical directors and maintenance of the responsibility chain across the registration life cycle.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail